NCT02259855View on ClinicalTrials.gov

Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2006

Primary Completion Date

October 1, 2008

Conditions
Hepatic Insufficiency
Interventions
DRUG

Tipranavir

DRUG

Ritonavir

DRUG

Pegylated interferon

DRUG

Ribavirin

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT02259855 - Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter